Yahoo
ASX - Delayed Quote AUD

PolyNovo Limited (PNV.AX)

0.9050 +0.0250 (+2.84%)
At close: October 30 at 4:10:11 PM GMT+11
Chart Range Bar
Loading chart for PNV.AX
  • Previous Close 0.8800
  • Open 0.8800
  • Bid 0.9050 x --
  • Ask 0.9100 x --
  • Day's Range 0.8800 - 0.9300
  • 52 Week Range 0.8100 - 1.3500
  • Volume 1,049,504
  • Avg. Volume 1,730,838
  • Market Cap (intraday) 625.212M
  • Beta (5Y Monthly) 1.35
  • PE Ratio (TTM) 90.50
  • EPS (TTM) 0.0100
  • Earnings Date Aug 26, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 1.25

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

polynovo.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

PNV.AX
26.42%
S&P/ASX 200 [XJO] (^AXJO)
2.22%

1-Year Return

PNV.AX
31.44%
S&P/ASX 200 [XJO] (^AXJO)
0.29%

3-Year Return

PNV.AX
21.65%
S&P/ASX 200 [XJO] (^AXJO)
31.37%

5-Year Return

PNV.AX
50.27%
S&P/ASX 200 [XJO] (^AXJO)
21.63%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY22
Revenue 11.9M
Earnings --
Profit Margin 0.00%

Q3

FY22

0
2M
4M
6M
8M
10M
0.0%

Analyst Insights

View More

Analyst Price Targets

0.95
1.25 Average
0.9050 Current
1.70 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.90%

  • Return on Assets (ttm)

    6.42%

  • Return on Equity (ttm)

    8.44%

  • Revenue (ttm)

    149.85M

  • Net Income Avi to Common (ttm)

    7.34M

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    35.47M

  • Total Debt/Equity (mrq)

    19.42%

  • Levered Free Cash Flow (ttm)

    -1.82M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: